Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

One year after severe COVID-19, T cells persist against SARS-CoV-2

One year after severe COVID-19, T cells persist against SARS-CoV-2

In a recently published article in the journal eBioMedicine, scientists have demonstrated that critically ill coronavirus disease 2019 (COVID-19) patients are capable of generating durable memory T cell response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for more than one year after hospital discharge.

28 Mar 2022

Virtual reality helps reduce COVID-19 vaccine hesitancy

Virtual reality helps reduce COVID-19 vaccine hesitancy

A new study investigates whether intention for vaccination is increased by a gamified immersive VR experience that shows how community immunity works.

28 Mar 2022

Northwestern scientists continue to advance the understanding of COVID-19

Northwestern scientists continue to advance the understanding of COVID-19

As the COVID-19 pandemic enters its third year, Northwestern Medicine scientists continue to help advance the understanding of the disease and its impact, from investigating antibody protection against COVID-19 reinfection to elevating women in academic research and highlighting racial and ethnic disparities in COVID-19 hospital mortality in Illinois.

28 Mar 2022

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly

Fourth COVID-19 vaccine dose substantially reduces mortality in the elderly

Researchers determine whether there was any reduction in the death rate in elderly COVID-19 patients following the second booster dose.

28 Mar 2022

Natural SARS-CoV-2 antibodies persist for six months in children

Natural SARS-CoV-2 antibodies persist for six months in children

Researchers investigate the presence of antibodies against SARS-CoV-2 in children between the ages of five and 19 after infection.

28 Mar 2022

Hybrid immunity and booster vaccination provides best protection against SARS-CoV-2 BA.1 and BA.2

Hybrid immunity and booster vaccination provides best protection against SARS-CoV-2 BA.1 and BA.2

Researchers analyze the effect of prior infection, vaccination, and hybrid immunity against SARS-CoV-2 BA.1 and BA.2 Omicron subvariant infections.

28 Mar 2022

Risk of death from SARS-CoV-2 infection higher than after COVID vaccination

Risk of death from SARS-CoV-2 infection higher than after COVID vaccination

Researchers investigate the risk of death following vaccination as compared to SARS-CoV-2 infection.

28 Mar 2022

Black patients with cancer experience worse outcomes after COVID-19 diagnosis

Black patients with cancer experience worse outcomes after COVID-19 diagnosis

Black patients with cancer experienced significantly worse outcomes after COVID-19 diagnosis than non-Hispanic white cancer patients in a study published March 28 in JAMA Network Open.

28 Mar 2022

Government announces £2.5 million package to improve transport accessibility for disabled people

Government announces £2.5 million package to improve transport accessibility for disabled people

The government has today (29 March 2022) announced a £2.5 million package to support disabled people travel more confidently on our transport network as it reopens after coronavirus (COVID-19).

28 Mar 2022

Evaluating severity of influenza infection in ferrets with COVID-19 history

Evaluating severity of influenza infection in ferrets with COVID-19 history

In a new study, researchers investigated the effect of SARS-CoV-2 exposure on the severity of influenza in ferrets.

28 Mar 2022

Examining differences in neurological manifestations induced by SARS-CoV-2 variants in hamsters

Examining differences in neurological manifestations induced by SARS-CoV-2 variants in hamsters

Researchers evaluated the neurological complications due to SARS-CoV-2 D614G strain, and variants of concern, Delta and Omicron in a hamster model.

28 Mar 2022

Dynamics of SARS-CoV-2 viral load in vaccinated and recovered individuals

Dynamics of SARS-CoV-2 viral load in vaccinated and recovered individuals

A new study assessed the dynamics of viral load of SARS-CoV-2 Omicron and Delta variants of concern post-vaccination and previous infection.

28 Mar 2022

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

Researchers applied a previously developed thermostable self-amplifying ribonucleic acid vaccine to COVID-19.

28 Mar 2022

The potential risk of SARS-CoV-2 transmission through fomites contaminated by hospitalized COVID-19 patients

The potential risk of SARS-CoV-2 transmission through fomites contaminated by hospitalized COVID-19 patients

Researchers evaluated the potential risk of SARS-CoV-2 transmission through fomites contaminated by hospitalized COVID-19 patients during coughing or intense moistening with saliva.

28 Mar 2022

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

A recent study investigated the potency and functionality of T-cell and humoral responses against the SARS-CoV-2 wild-type strain and its variants.

28 Mar 2022

Study investigates recombinant SARS-CoV-2 variants in immunocompromised individuals

Study investigates recombinant SARS-CoV-2 variants in immunocompromised individuals

Researchers identified the recombination of two SARS-CoV-2 variants.

28 Mar 2022

Study estimates protection against reinfection following primary SARS-CoV-2 infection

Study estimates protection against reinfection following primary SARS-CoV-2 infection

A recent study investigated the protection provided by the primary SARS-CoV-2 infection against reinfection.

28 Mar 2022

Benefits of heterotypic vaccination against variants of SARS-CoV-2

Benefits of heterotypic vaccination against variants of SARS-CoV-2

A new study evaluated the antibody responses against the newly emerged SARS-CoV-2 Omicron variant upon heterotypic vaccination in animal models.

28 Mar 2022

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Mathematical model of SARS-CoV-2 transmission tailored to the unique situation of China

Researchers designed a dynamic mathematical model to simulate the transmission of the SARS-CoV-2 Omicron variant in China and project its associated burden on healthcare facilities, should the zero-COVID-19 policy be lifted.

28 Mar 2022

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Study evaluates receptor-binding domain antibodies for their ability to bind and neutralize Omicron

Researchers evaluated the ability of RBD antibodies to bind to and neutralize SARS-CoV-2 Omicron variant.

28 Mar 2022

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.